Business Context and Reporting Period
Pavmed Inc. (PAVM), a Delaware corporation, filed this Form 8-K on September 9, 2026. The report details the entry into a material definitive agreement to facilitate an "at-the-market" equity offering.
Key Financial Metrics and Transaction Terms
- Maximum Offering Amount: $9,400,000 in shares of common stock.
- Sales Agent: A.G.P./Alliance Global Partners.
- Commission: 3.0% of aggregate gross sales prices.
- Legal Fee Reimbursement Cap (Execution): $65,000.
- Legal Fee Reimbursement (Quarterly): Up to $7,500 per calendar quarter.
- Legal Fee Reimbursement (Refresh): Up to $12,500 per program refresh.
- Use of Proceeds: Working capital and general corporate purposes.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.
Material Changes
The primary material change is the execution of a Sales Agreement on September 9, 2026, authorizing the Company to sell shares through an agent. This establishes a new mechanism for capital raising under an effective shelf registration statement (File No. 333-283994) declared effective on April 15, 2025.
Outlook, Risks, and Unusual Items
- Termination Rights: The agreement may be terminated by either party with ten business days' written notice, or immediately by the Agent under certain circumstances.
- Limitations: Sales are capped by the registered amount, authorized unissued shares, Form S-3 limits, and prospectus supplement limits.
- Legal Disclaimer: The agreement's representations and warranties are for the benefit of the parties and do not constitute factual information about the Company for other purposes.
Investor Verification Checklist
- Verify the current number of authorized but unissued shares to ensure the $9.4 million cap is feasible.
- Review the prospectus supplement filed on September 9, 2026, for specific share pricing mechanisms.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Assess the impact of the 3.0% commission and legal fees on net capital raised.